Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026
Key Highlights
- ➤HRS/BHB-1893 increased peak oxygen uptake 2.7 mL/kg/min at Week 52
- ➤KCCQ-CSS increased 17.3 points after 52 weeks of treatment
- ➤79% of patients achieved Valsalva LVOT gradient below 30 mmHg at Week 52
- ➤57% of patients remained on the 40 mg BID starting dose
- ➤Braveheart Bio plans fixed-dose Phase 2b TRUEHEART-HCM study in oHCM
Expert Statements
Su Zhang, Vice President and Head of Non-Oncology Clinical Development, Hengrui Pharma
“These 52-week data suggested the combination of clinical effect, tolerability, and simplicity in dosing of HRS/BHB-1893, which gives us growing confidence to proceed with our clinical development in China.”
Su Zhang, Vice President and Head of Non-Oncology Clinical Development, Hengrui Pharma
“We believe that it indicates HRS/BHB-1893 will be an effective and practical option for HCM patients.”
Travis Murdoch, M.D., President and Chief Executive Officer, Braveheart Bio
“These data reinforce the differentiated clinical profile of HRS/BHB-1893, suggesting encouraging efficacy, safety, and ease of use over a longer course of treatment.”
Travis Murdoch, M.D., President and Chief Executive Officer, Braveheart Bio
“The study data also suggest potential reverse-remodeling.”
Travis Murdoch, M.D., President and Chief Executive Officer, Braveheart Bio
“Taken together with data presented today on the mechanistic differentiation of HRS/BHB-1893 from preclinical work and the completed nHCM Phase 2 study, we believe that HRS/BHB-1893 could fundamentally address the biology of HCM, including diastolic dysfunction, across both forms of the disease.”
Theodore Abraham, M.D., Co-director of UCSF HCM Center of Excellence
“HCM has long been treated as a disease of obstruction, but the biology is more fundamental, and today's data begin to reflect that reality.”
Theodore Abraham, M.D., Co-director of UCSF HCM Center of Excellence
“These results suggest that it may be possible to engage that biology directly.”
Theodore Abraham, M.D., Co-director of UCSF HCM Center of Excellence
“The evidence of attenuated rebound after 52 weeks points to a treatment that is beginning to modify the structural and biological substrate of the disease.”
Theodore Abraham, M.D., Co-director of UCSF HCM Center of Excellence
“The diastolic findings in non-obstructive patients, consistent across preclinical models and the clinic, show that the same mechanism can improve ventricular relaxation and filling that have historically constrained this class.”
Theodore Abraham, M.D., Co-director of UCSF HCM Center of Excellence
“For patients living with HCM in all its forms, that could represent a meaningfully different kind of progress.”
HRS/BHB-1893 demonstrated meaningful improvements in exercise capacity and patient-reported outcomes, with rapid, deep, and durable left ventricular outflow tract (LVOT) gradient reduction at 52 weeks
Data support a highly simplified dosing regimen, with a majority of patients potentially served by the starting dose
Get started
Create a free account to read the full story.